Apogee Therapeutics Inc Dossier - Source-backed chat

Apogee Therapeutics Inc

APGENASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.55

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $135.07Price as of 2 Sep 2026

Data confidence Sign in to view data confidence

Market Cap $10.2B

Enterprise Value $10.1B

Shares Outstanding 75M diluted

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Apogee is principally an event-driven merger position rather than a conventional standalone biotechnology investment. AbbVie agreed to acquire all outstanding shares for $135.11 in cash, with closing expected in the third quarter of 2026 subject to customary conditions. The strategic rationale is supported by positive Phase 2 development of zumilokibart and a broader immunology pipeline, but the agreed consideration caps the modeled 12-month value absent a revised transaction. A Hold stance balances the contractual cash consideration against residual closing and clinical-development risks.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets11 analysts · as of 18 Aug 2026

Low · most bearish analyst$133.00

Mean target$134.85

High · most bullish analyst$135.11

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$135.1115%

Administrative or regulatory completion takes longer than the initial third-quarter expectation, but the transaction still closes within the 12-month horizon at the unchanged contractual consideration.

Base CaseCentral scenario

$134.8565%

Matches the consensus mean

The AbbVie transaction closes on substantially the announced terms and shareholders receive $135.11 per share in cash.

Bull CaseUpside scenario

$135.1120%

The acquisition closes within the announced third-quarter window, delivering the contractual $135.11 cash consideration. Strong zumilokibart evidence and the broader immunology pipeline support AbbVie's strategic commitment, but no higher consideration is assumed without primary-source evidence of a competing proposal.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

The definitive agreement specifies $135.11 in cash for each outstanding Apogee share.
Zumilokibart has completed Phase 2 in atopic dermatitis, with Phase 3 initiation targeted for the second half of 2026.
The pipeline offers additional strategic value through asthma, eosinophilic esophagitis and combination programs including APG279 and APG273.

Key Investment Risks

The acquisition remains subject to customary closing conditions, creating residual timing and completion risk.
Positive early- and mid-stage results may not predict safety or efficacy in larger or later-stage trials.
Clinical milestones, including zumilokibart Phase 3 initiation and APG279 data, could be delayed or produce less favorable outcomes.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.